These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 11905412)

  • 1. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
    Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
    Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
    Yeo W; Mok TS; Zee B; Leung TW; Lai PB; Lau WY; Koh J; Mo FK; Yu SC; Chan AT; Hui P; Ma B; Lam KC; Ho WM; Wong HT; Tang A; Johnson PJ
    J Natl Cancer Inst; 2005 Oct; 97(20):1532-8. PubMed ID: 16234567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
    Leung TW; Patt YZ; Lau WY; Ho SK; Yu SC; Chan AT; Mok TS; Yeo W; Liew CT; Leung NW; Tang AM; Johnson PJ
    Clin Cancer Res; 1999 Jul; 5(7):1676-81. PubMed ID: 10430068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.
    Kaseb AO; Shindoh J; Patt YZ; Roses RE; Zimmitti G; Lozano RD; Hassan MM; Hassabo HM; Curley SA; Aloia TA; Abbruzzese JL; Vauthey JN
    Cancer; 2013 Sep; 119(18):3334-42. PubMed ID: 23821538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.
    Yin XY; Lü MD; Liang LJ; Lai JM; Li DM; Kuang M
    World J Gastroenterol; 2005 Apr; 11(16):2526-9. PubMed ID: 15832431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
    Akçali Z; Akin E; Ozyilkan O
    Cancer; 2002 Nov; 95(9):2038-9; author reply 2039. PubMed ID: 12404300
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.
    Yang TS; Chang HK; Chen JS; Lin YC; Liau CT; Chang WC
    J Gastroenterol; 2004; 39(4):362-9. PubMed ID: 15168248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
    Jang JW; Park YM; Bae SH; Choi JY; Yoon SK; Chang UI; Nam SW; Kim BS
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):415-20. PubMed ID: 15235823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
    Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
    Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Eun JR; Lee HJ; Moon HJ; Kim TN; Kim JW; Chang JC
    Scand J Gastroenterol; 2009; 44(12):1477-86. PubMed ID: 19958061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
    Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
    Patt YZ; Hassan MM; Lozano RD; Brown TD; Vauthey JN; Curley SA; Ellis LM
    J Clin Oncol; 2003 Feb; 21(3):421-7. PubMed ID: 12560429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma.
    Lin CP; Yu HC; Cheng JS; Lai KH; Lo GH; Hsu PI; Lin CK; Chen HH; Lo CC; Liang HL; Tseng HH
    J Chin Med Assoc; 2004 Dec; 67(12):602-10. PubMed ID: 15779483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis.
    Chung YH; Song IH; Song BC; Lee GC; Koh MS; Yoon HK; Lee YS; Sung KB; Suh DJ
    Cancer; 2000 May; 88(9):1986-91. PubMed ID: 10813709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
    Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study.
    Komorizono Y; Kohara K; Oketani M; Maeda M; Shibathou T; Shigenobu S; Hiramine Y; Yamasaki N; Arima T; Kazuaki I; Arima T
    Dig Dis Sci; 2003 May; 48(5):877-81. PubMed ID: 12772783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
    Park JY; Ahn SH; Yoon YJ; Kim JK; Lee HW; Lee DY; Chon CY; Moon YM; Han KH
    Cancer; 2007 Jul; 110(1):129-37. PubMed ID: 17508408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
    Lim TY; Cheong JY; Cho SW; Sim SJ; Kim JS; Choi SJ; Choi JW; Kwon HC; Lee KM; Kim JK; Won JH; Yoo BM; Lee KJ; Hahm KB; Kim JH
    Korean J Hepatol; 2006 Mar; 12(1):65-73. PubMed ID: 16565607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma.
    Song MJ; Bae SH; Chun HJ; Choi JY; Yoon SK; Park JY; Han KH; Kim YS; Yim HJ; Um SH; Chung WJ; Hwang JS; Cho SB; Eun JR
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):739-46. PubMed ID: 25663125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.